These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16625329)

  • 1. Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
    Mori T; Hirota T; Ohashi Y; Kodaira S;
    Dis Colon Rectum; 2006 Jul; 49(7):982-92. PubMed ID: 16625329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
    Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
    Berger AC; Sigurdson ER; LeVoyer T; Hanlon A; Mayer RJ; Macdonald JS; Catalano PJ; Haller DG
    J Clin Oncol; 2005 Dec; 23(34):8706-12. PubMed ID: 16314630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.
    Sadahiro S; Suzuki T; Ishikawa K; Yasuda S; Tajima T; Makuuchi H; Saitoh T; Murayama C
    Cancer; 2004 Feb; 100(3):590-7. PubMed ID: 14745877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.
    Le Voyer TE; Sigurdson ER; Hanlon AL; Mayer RJ; Macdonald JS; Catalano PJ; Haller DG
    J Clin Oncol; 2003 Aug; 21(15):2912-9. PubMed ID: 12885809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma.
    Lee HY; Choi HJ; Park KJ; Shin JS; Kwon HC; Roh MS; Kim C
    Ann Surg Oncol; 2007 May; 14(5):1712-7. PubMed ID: 17253102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
    Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
    J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
    Smith RE; Colangelo L; Wieand HS; Begovic M; Wolmark N
    J Natl Cancer Inst; 2004 Aug; 96(15):1128-32. PubMed ID: 15292384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
    Kornmann M; Formentini A; Ette C; Henne-Bruns D; Kron M; Sander S; Baumann W; Kreuser ED; Staib L; Link KH
    Eur J Surg Oncol; 2008 Dec; 34(12):1316-21. PubMed ID: 18313881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
    Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
    J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
    J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of extramural deposits and extracapsular lymph node invasion in colon cancer.
    Al Sahaf O; Myers E; Jawad M; Browne TJ; Winter DC; Redmond HP
    Dis Colon Rectum; 2011 Aug; 54(8):982-8. PubMed ID: 21730787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons.
    Vaccaro CA; Im V; Rossi GL; Quintana GO; Benati ML; Perez de Arenaza D; Bonadeo FA
    Dis Colon Rectum; 2009 Jul; 52(7):1244-50. PubMed ID: 19571700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
    Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?
    Wang J; Kulaylat M; Rockette H; Hassett J; Rajput A; Dunn KB; Dayton M
    Ann Surg; 2009 Apr; 249(4):559-63. PubMed ID: 19300237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.